Agreements with Eli Lilly and Novo Nordisk aim to expand access to GLP-1 treatments through Medicare and new TrumpRx platform.
Washington, D.C. – November 7, 2025 — The Trump administration has announced sweeping agreements with pharmaceutical giants Eli Lilly and Novo Nordisk to dramatically reduce the cost of GLP-1 obesity and diabetes drugs, including Wegovy, Ozempic, Zepbound, and the upcoming Orforglipron. The deals are part of a broader push to make weight-loss medications more affordable and accessible for millions of Americans.
Under the new pricing model, patients using the administration’s forthcoming TrumpRx.gov platform will pay approximately $350 per month for injectable GLP-1 drugs, with prices expected to fall to $250 over the next two years for uninsured consumers. Daily pill versions, pending FDA approval, will start at $150 per month ABC News The White House.
Medicare and Medicaid Coverage Expansion
In a major policy shift, the agreements will also extend Medicare and Medicaid coverage to include obesity treatments for the first time. Previously excluded from federal reimbursement, drugs like Zepbound and Wegovy will now be available to eligible patients under public insurance programs The American Journal of Managed Care USA TODAY.
The administration emphasized that the deals align with its Most-Favored-Nation (MFN) pricing strategy, which ties U.S. drug prices to the lowest rates paid internationally. This move is expected to reduce annual expenditures on GLP-1 drugs, which currently rank among the highest-cost medications in the country The White House CNBC.
Industry and Political Implications
The announcement marks one of the most significant drug pricing reforms of the Trump presidency, with potential ripple effects across the pharmaceutical industry. While the administration did not reference the Medicare negotiation framework introduced under the Biden-era Inflation Reduction Act, analysts suggest that groundwork may have helped facilitate the current deals STAT.
The TrumpRx platform, launching in January 2026, will serve as a centralized hub for consumers to access discounted medications directly from manufacturers. The site will also guide users through eligibility for public coverage and out-of-pocket pricing tiers.
In short: The Trump administration has secured deals with Eli Lilly and Novo Nordisk to lower the cost of obesity drugs, expand Medicare and Medicaid coverage, and launch a new direct-to-consumer platform. Prices for GLP-1 treatments will drop significantly, marking a major shift in U.S. drug affordability policy.
Sources:
ABC News
TheWhite House Fact Sheet
The American Journal of Managed Care
STAT
USA TODAY
CNBC
